+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Antiviral treatment and vaccination for influenza A(H1N1)pdm09 virus: lessons learned from the pandemic



Antiviral treatment and vaccination for influenza A(H1N1)pdm09 virus: lessons learned from the pandemic



Enfermedades Infecciosas Y Microbiologia Clinica 30 Suppl 4: 49-53



The influenza pandemic that was declared by the World Health Organization in June 2009 created a new scenario for the use of influenza antivirals and vaccination. The new strain, influenza A(H1N1)pdm09, was resistant to amantadine and rimantadine, and the most frequently used antiviral was oseltamivir. Randomized studies were not performed comparing neuraminidase inhibitors with placebo. Nevertheless, experience from prospective and retrospective cohorts indicated that these drugs were useful for improving the prognosis of patients admitted to hospitals, especially for those with more severe disease. Treatment with oseltamivir was associated with a reduction in days of fever, length of hospital stay, use of mechanical ventilation and mortality. Treatment was more effective if it was begun within the first 48 h after the onset of symptoms, but it was also useful if begun later. A safe and effective vaccine to prevent disease from this new influenza strain was available in developed countries soon after the pandemic began; thus, the rate of adverse effects was comparable to that of seasonal influenza vaccines. The main barrier to its use was the concern of target populations about its necessity and safety. Therefore, the challenges for future pandemics will be to increase the population coverage of the vaccine in developed countries and to make it affordable for developing countries.

(PDF emailed within 0-6 h: $19.90)

Accession: 051595913

Download citation: RISBibTeXText

PMID: 23116793

DOI: 10.1016/S0213-005X(12)70105-2


Related references

Lessons learned from influenza A(H1N1)pdm09 pandemic response in Thailand. Emerging Infectious Diseases 18(7): 1058-1064, 2012

Pandemic vaccination strategies and influenza severe outcomes during the influenza A(H1N1)pdm09 pandemic and the post-pandemic influenza season: the Nordic experience. Euro Surveillance 21(16), 2017

Degree of adherence to recommended antiviral treatment during the pandemic and post-pandemic periods of influenza A(H1N1)pdm09 in 148 intensive care units in Spain. Medicina Intensiva 39(4): 222-233, 2017

Antibody responses against influenza A(H1N1)pdm09 virus after sequential vaccination with pandemic and seasonal influenza vaccines in Finnish healthcare professionals. Influenza and Other Respiratory Viruses 7(3): 431-438, 2013

Pandemic influenza A(H1N1)pdm09 seroprevalence in Sweden before and after the pandemic and the vaccination campaign in 2009. Plos One 7(12): E53511, 2013

Influenza pathogenesis: lessons learned from animal studies with H5N1, H1N1 Spanish, and pandemic H1N1 2009 influenza. Critical Care Medicine 38(4 Suppl): E21-E29, 2010

Differential Immune Profiles in Two Pandemic Influenza A(H1N1)pdm09 Virus Waves at Pandemic Epicenter. Archives of Medical Research 46(8): 651-658, 2016

Pandemic influenza and pregnancy revisited: lessons learned from 2009 pandemic influenza A (H1N1). American Journal of Obstetrics and Gynecology 204(6 Suppl 1): S1-S3, 2011

Reconstruction of the evolutionary dynamics of the A(H1N1)pdm09 influenza virus in Italy during the pandemic and post-pandemic phases. Plos One 7(11): E47517, 2013

Molecular and epidemiological analysis of pandemic and post-pandemic influenza A(H1N1)pdm09 virus from central India. Journal of Medical Virology 90(3): 447-455, 2017

Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany. Euro Surveillance 17(2), 2012

Biological characteristics of influenza A(H1N1)pdm09 virus circulating in West Siberia during pandemic and post-pandemic periods. Bulletin of Experimental Biology and Medicine 156(5): 673-679, 2014

The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 31(8): 1246-1254, 2013

Case registry systems for pandemic influenza A(H1N1)pdm09 in Europe: are there lessons for the future?. Euro Surveillance 17(19), 2012

The new pandemic influenza A/(H1N1)pdm09 virus: is it really "new"?. Journal of Preventive Medicine and Hygiene 57(1): E19-E22, 2018